This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Embryo Developmental Capacity After Egg Banking in an Ovum Donation Program

This study has been completed.
Information provided by (Responsible Party):
Carlos Simon, Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier:
First received: September 15, 2009
Last updated: April 21, 2015
Last verified: April 2015

For an efficient "egg banking" system, an equally efficient cryopreservation strategy that ensures the viability of the oocytes is required. Very recently, improved and new methods are yielding satisfactory results. In particular, vitrification is providing excellent results for both survival and clinical outcomes. However, to evaluate the over all out come there are other parameters to be considered. In this sense, capacity development of embryos generated after oocyte vitrification is a major factor when assessing the viability of vitrified oocytes. Accordingly, the evaluation of the capacity of vitrified oocytes to reach the blastocyst stage will be highly valuable to fully assess the effectiveness of the "egg banking" and its contribution to ovum donation programs.

The aim of this study is to evaluate the developmental capacity of vitrified oocytes by their ability to reach the blastocyst stage. The study includes oocyte donation cycles conducted with vitrified versus fresh oocytes.

Condition Intervention Phase
Infertility Other: IVF Other: Oocyte Vitrification Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)

Further study details as provided by Carlos Simon, Instituto Valenciano de Infertilidad, IVI VALENCIA:

Primary Outcome Measures:
  • Mean outcome measures will be survival, fertilization and blastocyst rates and clinical outcome. [ Time Frame: 10 months ]

Enrollment: 625
Study Start Date: September 2009
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: fresh
Embryo transfer with fresh oocytes
Other: IVF
Experimental: Frozen
Embryo transfer with vitrified oocytes
Other: Oocyte Vitrification


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18-35 year old
  • Normal response (8-15 follicles) to long protocol of ovarian stimulation with hCG
  • Donors with normal menstrual cycles (21-35 day duration)
  • Donors with BMI between 18-25 Kg/m2

Exclusion Criteria:

  • Donors with two or more previous miscarriages
  • Polycystic ovary syndrome
  • Donors with antecedents of poor embrionary quality not attributed to masculine factor
  • Donors with drop of estradiol of more than 10% or estradiol plateau.
  • Donors with a high response>20 oocytes and or levels above 3000pg/ml of estradiol the day of the administration of chorionic gonadotrophin (hCG)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00977821

IVI Valencia
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
  More Information

Responsible Party: Carlos Simon, Dr. Carlos Simon MD PhD, Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier: NCT00977821     History of Changes
Other Study ID Numbers: 0901-F-054-CS
Study First Received: September 15, 2009
Last Updated: April 21, 2015

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female processed this record on September 19, 2017